Cargando…
Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
Metastatic or recurrent tumors are the primary cause of cancer-related death. For prostate cancer, patients diagnosed with local disease have a 99% 5-year survival rate; however, this 5-year survival rate drops to 28% in patients with metastatic disease. This dramatic decline in survival has driven...
Autores principales: | Harris, Koran S., Kerr, Bethany A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485361/ https://www.ncbi.nlm.nih.gov/pubmed/28690641 http://dx.doi.org/10.1155/2017/8629234 |
Ejemplares similares
-
CD117/c-kit defines a prostate CSC-like subpopulation driving progression and TKI resistance
por: Harris, Koran S., et al.
Publicado: (2021) -
Bone Marrow-Derived Stem Cell Factor Regulates Prostate Cancer-Induced Shifts in Pre-Metastatic Niche Composition
por: Foster, Brittni M., et al.
Publicado: (2022) -
MTA1 drives malignant progression and bone metastasis in prostate cancer
por: Kumar, Avinash, et al.
Publicado: (2018) -
CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
por: Foster, Brittni M., et al.
Publicado: (2018) -
Dissociation of bone formation markers in bone metastasis of prostate cancer.
por: Koizumi, M., et al.
Publicado: (1997)